rivaroxaban

Details

Files
Generic Name:
rivaroxaban
Project Status:
Active
Therapeutic Area:
Venous thromboembolic events (VTE)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0750-000 - SR0750-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
N/A
Indications:
Treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Key Milestones2
Call for patient/clinician input open14-Jul-22
Call for patient/clinician input closed02-Sep-22
Clarification:

- No patient input submission received

Call for industry input open14-Jul-22
Call for industry input closed02-Sep-22
Review initiated12-Oct-22
Expert committee meeting (initial)24-Aug-23
Draft recommendation posted for stakeholder feedback
End of feedback period